Therapeutic trials in human transmissible spongiform encephalo-pathies: Recent advances and problems to address

Infectious Disorders - Drug Targets

Volumn 9, Issue 1, 2009, Pages 92-99

  Zerr, Inga ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

CJD; Diagnosis; Doxycyclin; Prion; Therapy

Indexed keywords

ACICLOVIR; AMANTADINE; AMPHOTERICIN B; AMPHOTERICIN B DERIVATIVE; ANTHRACYCLINE DERIVATIVE; ANTIMONIOTUNGSTATE; ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CHOLINESTERASE INHIBITOR; CLONAZEPAM; CONGO RED; CORTICOSTEROID DERIVATIVE; DEXTRAN SULFATE; DOXYCYCLINE; FLUPIRTINE; INTERFERON; MEPACRINE; NEUROLEPTIC AGENT; NOOTROPIC AGENT; PENTOSAN POLYSULFATE; PLACEBO; POLYAMINE DERIVATIVE; POLYANION; POLYENE ANTIBIOTIC AGENT; PRION PROTEIN; TETRAPYRROLE DERIVATIVE; UNINDEXED DRUG; VALPROIC ACID; VIDARABINE; ANALGESIC AGENT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT;

AKINESIA; ANXIETY DISORDER; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTINUOUS INFUSION; CREUTZFELDT JAKOB DISEASE; DEMENTIA; DEPRESSION; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; DRUG PENETRATION; DRUG TREATMENT FAILURE; EARLY DIAGNOSIS; FEASIBILITY STUDY; GENE MUTATION; HALLUCINATION; HUMAN; INCIDENCE; MOTOR DYSFUNCTION; MUSCLE RIGIDITY; MYOCLONUS; NEUROPSYCHOLOGY; NONHUMAN; PATIENT MONITORING; PHENOMENOLOGY; PREVALENCE; PRION DISEASE; PROGNOSIS; PSYCHOSIS; SURVIVAL; DISEASE TRANSMISSION; REVIEW; STATISTICS;

ANALGESICS; ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS; CLINICAL TRIALS AS TOPIC; CREUTZFELDT-JAKOB SYNDROME; HUMANS;

EID: 67649819814     PISSN: 18715265     EISSN: None     Source Type: Journal    
DOI: 10.2174/1871526510909010092     Document Type: Article

References (63)

1. Parchi P, Giese A, Capellari S, Brown P, Schulz-Schaeffer W, Windl O, et al. Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol. 1999; 46: 224-33.
2. Heinemann U, Krasnianski A, Meissner B, Varges D, Bartl M, Stoeck K, et al. Creutzfeldt-Jakob disease in Germany: a prospective 12-year surveillance. Brain. 2007; 130(5): 1350-9.
3. Zerr I, Schulz-Schaeffer WJ, Giese A, Bodemer M, Schröter A, Henkel K, et al. Current clinical diagnosis in CJD: identification of uncommon variants. Ann Neurol. 2000; 48: 323-9.
4. Parchi P, Castellani R, Capellari S, Ghetti B, Young K, Chen SG, et al. Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease. Ann Neurol. 1996; 39(6): 767-78.
5. Sanchez-Juan P, Green A, Ladogana A, Cuadrado-Corrales N, Sanchez-Valle R, Mitrova E, et al. CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology. 2006; 67(4): 637-43.
6. Tschampa HJ, Kallenberg K, Urbach H, Meissner B, C. N, Kretzschmar HA, et al. MRI in the diagnosis of sporadic Creutzfeldt-Jakob disease: a study on inter-observer agreement. Brain. 2005; 128(Pt 9): 2026-33.
7. Sanchez-Juan P, Sanchez-Valle R, Green A, Ladogana A, Cuadrado-Corrales N, Mitrova E, et al. Influence of timing on CSF tests value for Creutzfeldt-Jakob disease diagnosis. J Neurol. 2007; 254(7): 901-6.
8. Pocchiari M, Poupolo M, Croes EA, Budka H, Gelpi E, Collins S, et al. Predictors of survival in sporadic Creutzfeldt-Jakob disease and other human transmissible spongiform encephalopathies. Brain. 2004; 10: 2348-59.
9. Brown P, Cervenakova L, McShane L, Goldfarb LG, Bishop K, Bastian F, et al. Creutzfeldt-Jakob disease in a husband and wife. Neurology. 1998; 50(3): 684-8.
10. Zerr I, Poser S. Clinical diagnosis and differential diagnosis of CJD and vCJD. With special emphasis on laboratory tests. APMIS. 2002; 110: 88-98.
11. Cordery RJ, Hall M, Cipolotti L, Al-Sarraj S, O'Donovan DG, Davidson L, et al. Early cognitive decline in Creutzfeldt-Jakob disease associated with human growth hormone treatment. J Neurol Neurosurg Psychiatry. 2003; 74: 1412-6.
12. Cordery RJ, Alner K, Cipolotti L, Ron M, Kennedy A, Collinge M, et al. The neuropsychology of variant CJD: a comparative study with inherited and sporadic forms of prion disease. J Neurol Neurosurg Psychiatry. 2005; 76: 330-6.
13. Hamaguchi T, Kitamoto T, Sato T, Mizusawa H, Nakamura Y, Noguchi M, et al. Clinical diagnosis of MM2-type sporadic Creutzfeldt-Jakob disease. Neurology. 2005; 64: 643-8.
14. Brown P, Gibbs CJ, Jr., Rodgers-Johnson P, Asher DM, Sulima MP, Bacote A, et al. Human spongiform encephalopathy: the National Institutes of Health series of 300 cases of experimentally transmitted disease. Ann Neurol. 1994; 35(5): 513-29.
15. Krasnianski A, Meissner B, Schulz-Schaeffer W, Kallenberg K, Bartl M, Heinemann U, et al. Clinical features and diagnosis of the MM2 cortical subtype of sporadic Creutzfeldt-Jakob disease. Arch Neurol. 2006; 63(6): 876-80.
16. Zeidler M, Johnstone EC, Bamber RW, Dickens CM, Fisher CJ, Francis AF, et al. New variant Creutzfeldt-Jakob disease: psychiatric features. Lancet. 1997; 350(9082): 908-10.
17. Otto A, Zerr I, Lantsch M, Weidehaas K, Riedemann C, Poser S. Akinetic mutism as a classification criterion for the diagnosis of Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry. 1998; 64(4): 524-8.
18. Krasnianski A, Schulz-Schaeffer WJ, Kallenberg K, Meissner B, Collie DA, Roeber S, et al. Clinical findings and diagnostic tests in the MV-2 subtype of sporadic CJD. Brain. 2006; 129: 2288-96.
19. Meissner B, Westner I, Kallenberg K, Krasnianski A, Bartl M, Varges D, et al. Sporadic Creutzfeldt-Jakob disease: clinical and diagnostic characteristics of the rare VV1 type. Neurology. 2005; 65(10): 1544-50.
20. Boesenberg C, Schulz-Schaeffer WJ, Meissner B, Kallenberg K, Bartl M, Heinemann U, et al. Clinical course in young patients with sporadic Creutzfeldt-Jakob disease. Ann Neurol. 2005; 58: 533-43.
21. Trevitt CR, Collinge J. A systematic review of prion therapeutics in experimental models. Brain. 2006; 129: 2241-65.
22. Stewart LA, Rydzewska LH, Keogh GF, Knight RS. Systematic review of therapeutic interventions in human prion diseases. Neurology. 2008; 70(15): 1272-81.
23. Ludewigs H, Zuber C, Vana K, Nikles D, Zerr I, Weiss S. Therapeutic approaches for prion disorders. Expert Rev Anti Infect Ther. 2007; 5(4): 613-30.
24. Gresser I, Maury C, Chandler RL. Failure to modify scrapie in mice by administration of interferon or anti-interferon globulin. J Gen Virol. 1983; 64: 1387-9.
25. Grigoriev V, Adjou KT, Sales N, Simoneau S, Deslys JP, Seman M, et al. Effects of the polyene antibiotic derivative MS-8209 on the astrocyte lysosomal system of scrapie-infected hamsters. J Mol Neurosci. 2002; 18: 271-81.
26. Terzano MG, Montanari E, Calzetti S, Mancia D, Lechi A. The effect of amantadine on arousal and EEG patterns in Creutzfeldt-Jakob disease. Arch Neurol. 1983; 40(9): 555-9.
27. Beringue V, Deslys JP, Adjou KT, Dormont D. Creutzfeldt-Jakob disease: therapeutic stategies. Expert Opin Investig Drugs. 1997; 6(4): 345-8.
28. Ladogana A, Casaccia P, Ingrosso L, Cibati M, Salvatore M, Xi YG, et al. Sulphate polyanions prolong the incubation period of scrapie-infected hamsters. J Gen Virol. 1992; 73: 661-5.
29. Pocchiari M, Schmittinger S, Masullo C. Amphotericin B delays the incubation period of scrapie in intracerebrally inoculated hamsters. J Gen Virol. 1987.
30. Rudyk H, Knaggs MH, Vasiljevic S, Hope J, Birkett CR, Gilbert IH. Synthesis and evaluation of analogues of Congo red as potential compounds against transmissible spongiform encephalopathies. Eur J Med Chem. 2003; 38: 567-79.
31. Dealler S, Rainov N. Pentosan polysulfate as a prophylactic and therapeutic agent against prion disease. I Drugs. 2003; 6: 470-8.
32. Doh-ura K, Ishikawa K, Murakami-Kubo I, Sasaki K, Mohri S, Race R, et al. Treatement of transmissible spongiform encephalopathy by intraventricular drug infusion in animal models. J Virol. 2004; 78: 4999-5006.
33. Parry A, Baker I, Stacey R, Wimalaratna S. Long term survival in a patient with variant Creutzfeldt-Jakob disease treated with intraventricular pentosan polysulphate. J Neurol Neurosurg Psychiatry. 2007.
34. Whittle IR, Knight R, Will RG. Unsuccessful intraventricular pentosan polysulphate treatment of variant Creutzfeldt-Jakob disease. Acta Neurochir. 2006; 148(6): 677-9.
35. Todd N, Morrow J, Doh-ura K, Dealler S, O'Hare P, Farling M, et al. Cerebroventricular infusion of pentosan polysulphate in human vriant Creutzfeldt-Jakob disease. Journal of Infection. 2005; 50: 394-6.
36. Bone I, Belton L, Walker AS, Darbyshire J. Intraventricular pentosan polysulphate in human prion diseases: an observational study in the UK. Eur J Neurol. 2008; 15(5): 458-64.
37. Korth C, May BC, Cohen FE, Prusiner SB. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc Natl Acad Sci U S A. 2001; 98(17): 9836-41.
38. Klingenstein R, Löber S, Kujala P, Godsave S, Leliveld SR, Gmeiner P, et al. Tricyclic antidepressants, quinacrine and a novel, synthetic chimera thereof clear prions by destabilizing detergent-resistant membrane compartments. J Neurochem. 2006; 98(3): epub 2006 Jun 2.
39. Dohgu S, Yamauchi A, Takata F, Sawada Y, Higuchi S, Naito M, et al. Uptake and efflux of quinacrine, a candidate for the treatment of prion diseases, at the blood-brain barrier. Cell Mol Neurobiol. 2004; 24(2): 205-17.
40. Collins SJ, Lewis V, Brazier M, Hill AF, Fletcher A, Masters CL. Quinacrine does not prolong survival in a murine Creutzfeldt-Jakob disease model. Ann Neurol. 2002; 52(4): 503-6.
41. Haik S, Brandel JP, Salomon D, Sazdovitch V, Delasnerie-Laupretere N, Laplanche JL, et al. Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects. Neurology. 2004; 63(12): 2413-5.
42. Nakajima M, Yamada T, Kusuhara T, Furukawa H, Takahashi M, Yamauchi A, et al. Results of quinacrine administration to patients with Creutzfeldt-Jakob disease. Dement Geriatr Cogn Disord. 2004; 17: 158-63.
43. Otto M, Cepek L, Ratzka P, Doehlinger S, Boekhoff I, Wiltfang J, et al. Efficacy of flupirtine on cognitive function in patients with CJD: A double-blind study. Neurology. 2004; 62: 714-8.
44. Forloni G, Iussich S, Awan T, Colombo L, Angeretti N, Girola L, et al. Tetracyclines affect prion infectivity. Proc Natl Acad Sci. 2002; 99(16): 10849-54.
45. Forloni G, Colombo L, Girola L, Tagliavini F, Salmona M. Anti-amyloidogenic activity of tetracyclines: studies in vitro. FEBS Lett. 2001; 487(3): 404-7.
46. De Luigi A, Colombo L, Diomede L, Capobianco R, Mangieri M, Micclo C, et al. The efficacy of tetracyclines in peripheral and intracerebral prion infection. PLoS ONE. 2008; 3(3): e1888.
47. Ladogana A, Puopolo M, Croes EA, Budka H, Jarius C, Collins S, et al. Mortality from Creutzfeldt-Jakob disease and related disorders in Europe, Australia, and Canada. Neurology. 2005; 64: 1586-91.
48. Braaten AJ, Parsons TD, McCue R, Sellers A, Burns WJ. Neurocognitive differential diagnosis of dementing disease: Alzheimer's dementia, vascular dementia, frontotemporal dementia, and major depressive disorder. Int J Neurosci. 2006; 116: 1271-93.
49. Rossi G, Salmona M, Forloni G, Bugiani O, Tagliavini F. Therapeutic approaches to prion diseases. Clin Lab Med. 2003; 23: 187-308.
50. David AS, Grant R, Ballantyne JP. Unsuccessful treatment of Creutzfeldt-Jakob disease with acyclovir [letter]. Lancet. 1984; 1(8375): 512-3.
51. Newman PK. Acyclovir in Creutzfeldt-Jakob disease [letter]. Lancet. 1984; 1(8380).
52. Braham J. Amantadine in the treatment of Creutzfeldt-Jakob disease (letter). Arch Neurol. 1984; 41: 545-6.
53. Ratcliffe J, Rittman A, Wolf S, Verity MA. Creutzfeldt-Jakob disease with focal onset unsuccessfully treated with amantadine. Bull Los Angeles Neurol Soc. 1975; 40: 18-20.
54. Terzano MG, Mancia D, Manzoni GC. Periodic activities in Creutzfeldt-Jakob disease and epilepsy. Prog Clin Biol Res. 1983; 124(199): 199-226.
55. Braham J. Jakob-Creutzfeldt disease: treatement by amantadine. Br Med J. 1971; 4: 212-3.
56. Sanders WL, Dunn TL. Creutzfeldt-Jakob disease treated with amantidine. A report of two cases. J Neurol Neurosurg Psychiatry. 1973; 36(4): 581-4.
57. Sanders WL. Creutzfeldt-Jakob disease treated with amantadine. J Neurol Neurosurg Psychiatry. 1979; 42(10): 960-1.
58. Masullo C, Macchi G, Xi YG, Pocchiari M. Failure to ameliorate Creutzfeldt-Jakob disease with amphotericin B therapy [letter]. J Infect Dis. 1992; 165(4): 784-5.
59. Kovanen J, Haltia M, Cantell K. Failure of interferon to modify Creutzfeldt-Jakob disease. British Medical Journal. 1980; 280: 902.
60. Benito-Leon J. Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects. Neurology. 2005; 64: 1824.
61. Satoh K, Shirabe S, Eguchi K, Yamauchi A, Kataoka Y, Niwa M. Toxicity of quinacrine can be reduced by co-administration of P-glycoprotein inhibitor in sporadic Creutzfeldt-Jakob disease. Cell Mol Neurobiol. 2004; 24: 873-5.
62. Scoaazec JY, Krolak-Salmon P, Casez O, Besson G, Thobois S, Kopp N. Quinacrine-induced cytolytic hepatitis in sporadic Creutzfeldt-Jakob disease. Ann Neurol. 2003; 53: 546-7.
63. Furlow TJ, Whitley RJ, Wilmes FJ. Repeated suppression of Creutzfeldt-Jakob disease with vidarabine [letter]. Lancet. 1982; 2(8297): 564-5.